EQT exits from Galderma via record block trade By Investing.com

EQT completed its final sell-down in Galderma, placing ~34.0 million shares for aggregate gross proceeds of ~CHF 4.9 billion via an accelerated bookbuild; EQT VIII received ~CHF 1.3 billion. Under EQT ownership (carve-out from Nestlé in 2019), Galderma grew revenue from $2.8bn (2018) to $5.2bn (2025), LTM organic growth accelerated to ~18% in 2025, and EBITDA rose from $520m to $1.2bn. EQT has realized ~CHF 21bn (~$26bn) since the IPO, and this exit—one of the largest sponsor-backed block trades ever—represents the largest value-creation outcome in EQT’s history.

Analysis

When a sponsor-backed position is fully moved into the public market, the immediate structural effect is removal of a recurring forced-supply tail; that typically compresses realized volatility for the stock and shifts valuation drivers from cap-extractive exit planning to organic growth and M&A optionality. Expect a regime change over 3–12 months where multiples are more sensitive to topline cadence, R&D readouts and margin durability rather than exit-timing narratives.

For the underlying healthcare franchise, successful early-stage biologic adoption would be a multi-year earnings amplifier because biologics carry both higher ASPs and more durable revenue streams than consumer SKUs; a 5–10% penetration swing in key geographies could move EBITDA by several hundred million CHF over 24–36 months and re-rate the business toward specialty-pharma comps. Conversely, elective aesthetic demand is cyclical — a 10–15% sequential softness in high-end markets can wipe 100–200bps off group margins quickly, making short-term sensitivity to macro discretionary spending acute.

From the sponsor/asset manager perspective, large realizations reset capital deployment optics: with dry powder elevated and public comps richer, sustaining prior IRRs requires either faster bolt-on consolidation or multiple arbitrage via tuck-ins. That dynamic creates a mid-cycle catalyst set — accelerated M&A or yield-generating return-of-capital programs — but also a risk that fee-bearing AUM growth lags, pressuring earnings per share for the manager over 6–18 months.

The contrarian risk is that the market is overweight the benign supply narrative and underweights execution risk: if R&D outcomes disappoint or consumer demand softens, the newly permanent public float magnifies downside because passive and thematic funds dominate allocation flows. That asymmetric risk profile argues for event-driven entry points rather than buy-and-hold exposure without hedges.

Key Decisions for Investors

• Long EQT (EQT) — buy a 2–4% portfolio position, time horizon 6–12 months. Rationale: capture potential re-rating from realized value crystallizations and possible buyback/dividend deployment; target +20–30% upside vs current, stop-loss 12% and take profits on any 25–30% run-up.
• Long Galderma (SIX:GALD) vs Short Estee Lauder (EL) — pair trade sized 1:1 by beta, horizon 9–18 months. Rationale: asymmetric upside from biologic adoption and margin mix shift vs broader prestige peer trading on slower growth; expect GALD to outperform EL by 15–25 percentage points if product uptake meets conservative adoption assumptions.
• Buy GALD 12–18 month call spread (debit) — long OTM call / sell higher strike call to finance ~50–60% of premium. Entry on any >5% pullback. R/R: limited downside to premium paid, levered upside to successful uptake/readouts; use as replacement for outright long to limit capital at risk.
• Tactical hedge for EQT exposure — purchase 3–6 month put protection sized to 30–50% of EQT long position if market-wide volatility rises or discretionary spending weakness appears. Cost justified if downside >10% within 3 months; reduces asymmetric risk from concentrated sponsor-realization narrative.